Synthetic HNK-1 containing glycans provide insight into binding properties of serum antibodies from MAG-neuropathy patients
Publication date
2022-07-25
Editors
Advisors
Supervisors
Document Type
/dk/atira/pure/researchoutput/researchoutputtypes/workingpaper/preprint
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Anti-myelin-associated glycoprotein (anti-MAG) neuropathy is an autoimmune disease in which IgM autoantibodies target glycoconjugates of peripheral nerves resulting in progressive demyelination. To examine fine specificities of serum IgM autoantibodies and develop a more robust platform for diagnosis and disease monitoring, we describe here a chemoenzymatic approach that readily provided a panel of HNK-1 containing oligosaccharides presented on type 2 oligo-N-acetyl lactosamine (LacNAc) chains typical of glycosphingolipids. The compounds were prepared by a chemoenzymatic strategy in which an oligo-LacNAc structure was assembled enzymatically and then subjected to protecting group manipulation to chemically install a 3-O-sulfate glucuronic acid moiety. The synthetic strategy is highly divergent and made it possible to prepare from key precursors, additional compounds lacking sulfate of HNK-1 and derivatives in which the HNK-1 epitope is replaced by sulfate or sialic acid. The oligosaccharides were printed as a microarray to examine binding specificities of several monoclonal antibodies and serum antibodies of anti-MAG neuropathy patients. Surprisingly, three distinct patient subgroups were identified with variable dependance on the length of the LacNAc chain and sulfation of the glucuronyl moiety. In most cases, a lacto-neohexaose backbone was required for binding indicating the antibodies target corresponding glycosphingolipids.
Keywords
Chemoenzymatic synthesis, Glycans, Microarray, Auto-antibodies, Anti-MAGneuropathy
Citation
Bunyatov, M, Wolfert, M A, Huizinga, R, Schreurs, M W J, Jacobs, B C & Boons, G-J 2022 'Synthetic HNK-1 containing glycans provide insight into binding properties of serum antibodies from MAG-neuropathy patients' bioRxiv. https://doi.org/10.1101/2022.07.25.501369